Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst

Newly unveiled data will likely establish CAR-T therapies as the new standard of care in certain patients with aggressive B-cell lymphoma after one prior therapy. For Gilead Sciences’ Yescarta, that indication could mean $1.5 billion in sales over time.